改良儿童方案治疗18-30岁经典型霍奇金淋巴瘤:多中心II期临床试验结果
该II期试验评估改良儿童风险分层方案在18-30岁经典型霍奇金淋巴瘤患者中的安全性和有效性,主要终点为神经毒性率。3级神经毒性发生率为11%(80%CI 5-19%),不能排除真实神经病变率>15%;总体缓解率100%,完全缓解率40%,12个月无病生存率91%。结果表明该风险分层儿童联合模式治疗方案可用于年轻成人且无显著不可逆神经病变。
要点
- 改良儿童风险分层方案在18-30岁cHL中3级神经毒性率为11%(80%CI 5-19%)
- 总体缓解率100%,完全缓解率40%,12个月无病生存率91%
- 神经病变及生活质量下降 largely reversible,无显著不可逆神经毒性
核心结论
- 风险分层的儿童联合模式治疗方案可安全用于18-30岁经典型霍奇金淋巴瘤年轻成人,不引起显著不可逆神经病变。
研究设计与样本
- 多中心II期临床试验(CRUK/08/012),纳入18-30岁经典型霍奇金淋巴瘤年轻成人,采用改良儿童风险分层方案,主要终点为神经毒性率。
主要发现
- 3级神经毒性发生率为11%(80%CI 5-19%),不能排除真实神经病变率>15%。
- 神经病变及伴随的生活质量下降 largely reversible。
- 总体缓解率为100%,完全缓解率为40%,12个月无病生存率为91%。
临床怎么用
- 在18-30岁经典型霍奇金淋巴瘤年轻成人中,可考虑采用风险分层的儿童联合模式治疗方案,需监测神经毒性。
局限性
- 3级神经毒性11%的80%CI上限达19%,不能排除真实神经病变率>15%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk-stratified protocol in young adults (18-30 years) with classical Hodgkin Lymphoma. The primary end-point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5-19%); a true rate of neuropathy of >15% cannot be excluded. Neuropathy and associated deterioration in quality of life was largely reversible. The overall response rate was 100% with 40% complete remission (CR) rate. Twelve months disease-free survival (DFS) was 91%. We demonstrate that a risk-stratified paediatric combined modality treatment approach can be delivered to young adults without significant irreversible neuropathy.
引用
- Townsend W, Leong S, Hoskin P, et al. Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012). Br J Haematol. 2019. PMID: 31710702. doi:10.1111/bjh.16296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。